ArticleJournal of animal science2025
Effects of β-mannanase on intestinal health and growth performance of nursery to growing pigs fed diets with DDGS.
Article in Journal of animal science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Investigation of nutritional and functional roles of β-mannanase on intestinal health and growth performance of nursery pigs fed low-cost formulated diets with high phytase inclusion.Journal of animal science · 2026Article
- Evaluation ofTranslational animal science · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
A total of 84 pigs (17.6 ± 2.8 kg initial body weight at 6 wk of age) were used in a 40-d trial to evaluate the effects of dietary supplemental β-mannanase (400 U/kg feed, CTCBIO Inc., Seoul, Korea) on growth performance, digesta viscosity, ileal nutrient digestibility, and intestinal health of pigs during the nursery to grower phase. Pigs were allotted to two treatments (14 pens per treatment, 3 pigs per pen) based on a randomized complete block design with sex as a block. Experimental diets included corn (starter: 50%; grower: 57%), soybean meal (starter: 27%; grower: 20%), and 20% distillers dried grains with solubles with or without 400 U β-mannanase/kg feed. Growth performance (average daily gain, average daily feed intake, and gain-to-feed ratio) was recorded weekly. Plasma was collected on day 35 to quantify tumor necrosis factor-alpha (TNF-α) and malondialdehyde (MDA). On day 35, 0.3% titanium oxide was added as an indigestible marker to the diets for an additional 4-d feeding. On day 40, 16 pigs (1 pig per pen, 8 pens per treatment) were euthanized to collect digesta from jejunum, ileum, and colon (to measure viscosity and pH value) and to collect tissues from duodenum, jejunum, and ileum (for histomorphology, TNF-α, and MDA evaluation). Supplementation of β-mannanase reduced (P < 0.05) viscosity of jejunal digesta (2.52 to 1.97 cP, respectively), increased pH of colon digesta (5.99 to 6.33), and tended to reduce (P = 0.078) TNF-α concentration (7.94 to 6.46 pg/mg) in jejunal mucosa. Supplementation of β-mannanase decreased (P < 0.05) jejunal crypt depth (249 to 212 µm), whereas increasing (P < 0.05) ileal villus height (377 to 432 µm) and villus height to crypt depth ratios in both the jejunum (1.58 to 2.10) and ileum (1.65 to 2.02). Supplementation of β-mannanase increased ileal digestibility of neutral detergent fiber (31.3% to 41.1%) and acid detergent fiber (26.8% to 38.7%), whereas improving (P < 0.05) G:F ratio during the starter (0.593 to 0.617) and the overall period (0.572 to 0.589). Collectively, dietary β-mannanase (400 U/kg) could improve feed efficiency by decreasing digesta viscosity and increasing nutrient digestibility and could also maintain intestinal health by improving intestinal morphology and reducing inflammatory response.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.